Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (May 2024)
26 slides from Sona Nanotech's investor presentation, May 2024
Slide 1: Empowering Immuno-Oncology Therapies By Stimulating the Immune System
Empowering Immuno-Oncology Therapies By Stimulating the Immune System: A Novel 1-2 Punch Against Cancer May 2024 sonanano.com CSE: SONA | OTCQB: SNANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses this presentation due to risks and uncertainties affecting Sona activities or developments tha
Slide 3: Proprietary, Uniquely Biocompatible Nanotechnology for a More Effective and Gentler Cancer Therapy
Using Proprietary, Uniquely Biocompatible Nanotechnology for a More Effective and Gentler Cancer Therapy That Enables Immunology Sona’s Proprietary Technology Sona’s Gold Nanorod Advantages • Patented, biocompatible, Uniquely Biocompatible: • Sona surfactant uses no toxic CTAB * proprietary gold nan
Slide 4: Sona's Cancer Therapy Shrinks Tumors and Is Prescribed With Current Immunotherapies
Sona’s Cancer Therapy Shrinks Tumors, And Is Prescribed With Current Immunotherapies, Making Those Drugs Work Much Better Sona’s ‘Targeted Hyperthermia Therapy’ for Cancer 1. Tumor is injected with Sona’s biocompatible gold nanorods 2. Sona’s light energy device is applied to the tumor 3. Cancer cel
Slide 5: $31 Billion Was Spent On Immuno-Oncology Drugs In The U.S. In 2021
$31 Billion Was Spent On Immuno-Oncology (“IO”) Drugs In The U.S. For Solid Cancers In 2021 Top Immunotherapy Drugs by 2021 Sales (USD Billions) $- $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 $14.0 $16.0 $18.0 $20.0 Keytruda (Merck) Pembrolizumab Opdivo (BMS) Nivolumab Tecentriq (Roche) Atezolizumab Imfinzi (As
Slide 6: IO Therapies Vastly Improve Survival Rates Vs. Chemo Alone
IO Therapies Vastly Improve Survival Rates Vs. Chemo Alone 5yr Overall Survial Rate 20% Named 18% 16% ‘Breakthrough of 14% the Year’ in 2013 12% by Science 10% 8% journal, 6% immunotherapy 4% enables the 2% 0% immune system to Metastatic nonsquamous NSCLC Metastatic squamous NSCLC fight cancer itsel
Slide 7: But IO Therapy Response Rates Are Still Very Limited
But IO Therapy Response Rates Are Still Very Limited Immunotherapy Response Rate in Study of 1678 Patients by Cancer Type 45% 40% 35% 30% Average response rate was only 21% 25% to immunotherapy 20% 15% 10% 5% 0% Note: Patients treated with anti–programmed cell death 1 or programmed cell death ligand
Slide 8: Sona's Study Results Show Therapy Combined With Immunotherapy Drives Better Results
Sona’s Study Results Show Its Therapy Combined With Immunotherapy Drives Significantly Better Results Preclinical Research Study Background – Initial Results Study (Triple Negative Breast Cancer Mouse Tumor Model, n=6) Tumors left unchecked continue to grow Tumors treated with combination of THT and
Slide 9: Main Reason IO Success Can Be Constrained Is Weak Tumor Antigens
The Main Reason IO Success On Its Own Can Be Constrained Is If Tumor Antigens Presented Are Too Weak To Elicit An Immune Response Sources of Immunotherapy Resistance 1. Weak tumor antigen or loss of tumor-antigen More of a good expression thing isn’t necessarily better: 2. Upregulation of immune-che
Slide 10: How Can Sona Cause Unexposed Antigens to Be Presented to the Immune System?
Many Unexposed Antigens Exist in Tumors But How Can Sona Cause Them to be Presented to the Immune System? Heating cancer cells gently causes them to die by apoptosis which causes the release of neo-antigens Sona’s therapy primes the tumor microenvironment to present neo-antigens, thereby enabling im
Slide 11: THT Uses NIR Light To Heat Nanorod-Saturated Tumors From Inside Out
Targeted Hyperthermia Therapy (“THT”) Uses NIR Light To Heat Nanorod-Saturated Tumors From Inside Out, Gently A Two-Step Therapy 1. 2. Delivering a 1-2 Inject Biocompatible Shine NIR Light Tuned Gold Nanorods Intratumorally to 850nm on Tumor Punch: 1. Heat causes cancer cell apoptosis, shrinking tum
Slide 12: THT Heats Tumors to 41-48 °C to Kill Cancer Cells
THT’s ‘Hyperthermia’ Approach Heats Tumors to 41-48 °C – Enough to Kill Cancer Cells, But Not Enough to Harm Healthy Cells . Cancer cell death by apoptosis Apoptosis: A type of cell death in which a series of molecular steps in a cell lead to its death. This is one method the body uses to get rid of
Slide 13: Sona's THT Therapy is Selective and Efficient
While Cancer Cell Death by Apoptosis Can Be Stimulated In a Variety of Ways, Sona’s THT Therapy is Selective and Efficient Rationale for Sona’s Targeted Hyperthermia Therapy (THT) • Gold nanorods (GNRs) are the most efficient gold nanoparticles at converting light energy into heat potentially minimi
Slide 14: Intended Use Is Adjunctive To Current Standard Of Care
Intended Use Is As Adjunctive To Current Standard Of Care, With The Goal To Become The Standard of Care AJCC Stages IIIB, IIIC, (N2c, THT Intended Use N3), Stage IV (M1) o To create hyperthermia in M2 ruled out PET / PET-CT superficial tumors of patients Criteria for with locally advanced cutaneous
Slide 15: Initial Target Indication Is Late-stage, Unresectable Melanoma
Initial Target Indication Is Late-stage, Unresectable Melanoma THT Target Indication o Adjunctive treatment for patients with unresectable locally advanced cutaneous melanoma with in-transit or satellite metastases. o Stage IIIB, IIIC (N2c or N3) and Stage IV (M1) melanoma. o Failed immunotherapy (f
Slide 16: Sona's THT Therapy is Proprietary And Will Benefit From IP Protection
Sona’s THT Therapy is Proprietary And Will Benefit From IP Protection Sona’s Four Sources of IP Advantage Patents: Two Device System: • Method for Manufacture of Biocompatible Gold Nanorods • Once approved by regulators, Sona’s light • Issued: USA and South Korea. Pending: PCT, Canada, EU. device ma
Slide 17: Key Elements Of Sona's THT Concept Have Been Proven
Key Elements Of Sona’s THT Concept Have Been Proven Previously Done/Approved: - Heat used to kill cancer cells - Photothermal treatment using infrared light devices • Lack of structural complexity - FDA has approved nanoparticles for injection into humans in prior clinical trials(1) - THT efficacy i
Slide 18: Building the Safety and Efficacy Data Required for a First in Human Study
Building the Safety and Efficacy Data Required by Regulators for a ‘First in Human’ Pivotal Phase 1 Clinical Study Research Current Efficacy Study at Dalhousie Study University: Evaluation of Sona Nanotech’s Gold Nanoparticle-Mediated Photothermal Therapy in Combination with Intralesional Immune Mod
Slide 19: Research Study Background – Metrics of Success
Research Study Background – Metrics of Success Preclinical Study Success Will Be Assessed By The Extent To Which: Tumor Shrinkage Enhanced Immune Abscopal Effects are Response Observed • THT causes tumor • Use of THT with certain • Immune responses created in volume reduction in immunotherapies is r
Slide 20: Initial Data Shows Synergistic Effect of THT and IL-2
Initial Data Shows Synergistic Effect of Combining Sona’s THT and Standard Immunotherapy Agent IL-2 Preclinical Study Research Study Background – Initial Results (Triple Negative Breast Cancer Mouse Tumor Model, n=6) Tumor Volume Tumor Volume (without error bars) (with error bars) A single dose of T
Slide 21: Development Plan Guided By Leading Physicians And Multiple FDA Interactions
Sona’s Development Plan For THT Has Been Guided Of A Panel Of Leading Physicians In The U.S. And Multiple FDA Interactions Stakeholder Engagement EXCITE International Panel Members: - Three surgical oncologists from leading U.S. cancer centres - Four physicians representing different U.S. payer orga
Slide 22: Moving Quickly Towards Regulatory Filings and First-in-Human Study
Moving Quickly Towards Regulatory Filings and First-in-Human Study 1. Selection of pre-clinical study partners, plans and initial safety study results • Utilizing pre-existing research & advisory groups to conduct studies in the most cost-effective ways 2. Panel of leading EXCITE International exper
Slide 23: Sona Has Engineered the Right 'Gene Pool' to Develop Its Cancer Therapy
Sona Has Engineered the Right ‘Gene Pool’ to Develop Its Cancer Therapy Board Mark Lievonen Walter Strapps PhD Neil Fraser Jim Megann Chairman Director Director Director o Led vaccine maker Sanofi- o CEO of Khosla Ventures o Led Medtronic Canada for ~20 o 25 years of experience in Pasteur to a billi
Slide 24: Key Development Studies For THT Will Provide Many Catalysts
Key Development Studies For THT Will Provide Many Catatlysts 2024-2025 Anticipated Milestones 2024 2025 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Targeted Initial Efficacy Pilot Safety Biocompatibility Chemical CDMO GNRs Initiate First Hyperthermia Study Results Study Results Feasibility Study Results Characterization R
Slide 25: Market Capitalization, Ownership, Capital Structure
As of April 26, 2024 Market Capitalization Ownership Share Price C$0.42 Board and Market Cap. C$42M 16% Management 52 Week High/Low $0.56/$0.075 Capital Structure Issued & Outstanding 99M Options 6.0M Warrants 3.1M Public 84% sonanano.com 25
Slide 26: Biocompatible Gold Nanorod Technology
BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY David Regan david@sonanano.com CEO Sona Nanotech Inc. +1 902 448 1416 CSE: SONA | OTCQB: SNANF sonanano.com 26